Combined analyses of paraoxonase-1 and IGF-2 polymorphism in polycystic ovary syndrome;Kombinierte analyse von paraoxonase-1- und IGF-2- polymorphismen bei polyzystischem ovarsyndrom

Deutsche Medizinische Wochenschrift

Volumn 134, Issue 20, 2009, Pages 1040-1046

  Knebel, B ^a   Janssen, O E ^b   Hahn, S ^c   Nitzgen, U ^a   Jacob, S ^a   Haas, J ^a   MacK, S ^a   Muller Wieland D ^a   Kotzka, J ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b ENDOKRINOLOGIKUM HAMBURG   (Germany)

^c DEPARTMENT OF CARDIOLOGY   (Germany)

Author keywords

Adipositas; IGF 2; Lipid metabolism; PCOS; Polycystic ovary syndrome; PON 1

Indexed keywords

ALANINE; ARYLDIALKYLPHOSPHATASE 1; CYSTEINE; GLYCINE; INSULIN; LIPID; SOMATOMEDIN; SOMATOMEDIN B; THREONINE; ARYLDIALKYLPHOSPHATASE;

ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC REGULATION; GENOTYPE; HUMAN; INSULIN SENSITIVITY; LIPID METABOLISM; MAJOR CLINICAL STUDY; MOLECULAR GENETICS; OVARY POLYCYSTIC DISEASE; PHENOTYPE; SINGLE NUCLEOTIDE POLYMORPHISM; CASE CONTROL STUDY; GENETIC POLYMORPHISM; GENETICS; INSULIN RESISTANCE; METABOLISM; PROMOTER REGION; STATISTICAL MODEL;

ADULT; ARYLDIALKYLPHOSPHATASE; BODY MASS INDEX; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR II; LIPID METABOLISM; LOGISTIC MODELS; POLYCYSTIC OVARY SYNDROME; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC;

EID: 65649135181     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0029-1222564     Document Type: Article

References (24)

1. Altshuler D, Hirschhorn JN, Klannemark M et al. The common PPARy Prol2Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000; 26: 76-80
2. Brophy VH, Jampsa RL, Clendenning JB et al. Effects of 5' regulatory-region polymorphism on paraoxonase-gene (PON1) expression. American Journal of Human Genetics 2001; 68:1428-1436
3. Deeb SS, Fajas L, Nemoto M et al. A Prol 2Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998; 20: 284-287
4. Diamanti-Kandarakis E, Kandarakis H, Legro RS. The role of genes and environment in the etiology of PCOS. Endocrine 2006; 30:19-26
5. Dunaif A Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocrine Rev 1997; 18: 774-800
6. Dursun P, Demirta E Bayrak A et al. Decreased serum paraoxonase 1 (PON1) activity: an additional risk factor for atherosclerotic heart disease in patients with PCOS? Hum Reprod 2006; 21: 104-108
7. Fenkci IV, Serteser M, Fenkci S et al. Paraoxonase levels in women with polycystic ovary syndrome. J Reprod Med 2007; 52: 879-883
8. Hahn S, Fingerhut A, Khomtsiv U et al. The peroxisome proliferator activated receptor gamma Prol2Ala polymorphism is associated with a lower hirsutism score and increased insulin sensitivity in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2005; 62: 573-579
9. Hudecova M, Holte J, Olovsson M et al. Long-term follow-up of patients with polycystic ovary syndrome: reproductive outcome and ovarian reserve. Hum Reprod 2009doi:10.1093/humrep/den482
10. Leviev I, James RW. Promoter polymorphisms of the human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol 2000; 20: 516-521
11. Leviev I, Righetti A, James RW. Paraoxonase promoter polymorphism T(- 107)C and relative paraoxonase deficiency as determinants of risk of coronary artery disease. J Molec Med 2001; 79: 457-463
12. Luque-Ramirez M, San Millän JL, Escobar-Morreale HF. Genomic variants in polycystic ovary syndrome. Clin Chim Acta 2006; 366: 14-26
13. On F, Matarese G, Di Biase S et al. Exon 6 and 2 peroxysome proliferator- activated receptor polymorphisms in polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88: 5887-5892
14. Rqjkhowa M, Neary RH, Kumpatla P et al. Altered composition of high density lipoproteins in women with the polycystic ovary cyndrome. J Clin Endocrinol Metab 1997; 82: 3389-3394
15. Rebuffe-Scrive M, Cullberg G, Lundberg PA et al. Anthropometric variables and metabolism in polycystic ovarian disease. Horm Metab Res 1989; 21: 391-397
16. Rodriguez S, Gaunt TR O'Dell SD et al. Haplotypic analyses of the IGF2- INS-TH gene cluster in relation to cardiovascular risk traits. Hum Molec Genet 2004; 13:715-725
17. Safesi M, Bravo-Vera R Sheikh A et al. Pathogenesis of the polycystic ovary syndrome: What is the role of obesity? Metabolism 2004; 53: 358-376
18. San Millän JL, Cortön M, Villuendas G et al. Association of the polycystic ovary syndrome with genomic variants related to insulin resistance, type 2 diabetes mellitus, and obesity. J Clin Endocrinol Metab 2004; 89:2640-2646
19. Suehiro T, Nakamuraa T, Inouea M et al. A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression. Atherosclerosis 2000;150:295-298
20. Tadokoro K, Fujii H, Inoue T et al. Polymerase chain reaction (PCR) for detection of Apal polymorphism at the insulin like growth factor II gene (IGF2). Nucleic Acids Res 1991; 19: 6967-
21. Ukkola O, Sun G, Bouchard C. Insulin-like growth factor 2 (IGF2) and IGF- binding protein 1 (IGFBP1) gene variants are associated with overfee- ding-induced metabolic changes. Diabetologia 2001; 44: 2231-2236
22. Unluturk U, Harmanci A, Kocaefe G et al. The genetic basis of the polycystic ovary syndrome: A literature review including discussion of PPAR-y. PPAR Res 2007doi:10.1155/2007/
23. Urbanek M. The genetics of the polycystic ovary syndrome. Nat Clin Pract Endocrinol Metab 2007; 3: 103-111
24. Venkatesan AM, Dunaif A, Corbould A. Insulin resistance in polycystic ovary syndrome: progress and paradoxes. Recent Prog Horm Res 2001; 56: 295-308